Anti-Cemiplimab Antibodies are introduced in Bio-Rad

Anti-Cemiplimab Antibodies are introduced in Bio-Rad ...

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic equipment, has introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1, which is suitable for bioanalysis and drug monitoring.

Cemiplimab acts as a checkpoint inhibitor by binding to PD-1 on T cells, blocking the interaction with its ligands, PD-L1, and PD-L2, thereby activating T cells to attack cancer cells. Three fully human IgG1 antibodies with varying levels of affinity are ideal for site-directed conjugation or quick conversion to a bivalent Fab or an Ig-like format within an hour.

The recombinant antibodies are generated using the Human Combinatorial Antibody Libraries (HuCAL) and CysDisplay, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reactants. The recombinant process has resulted in batch-to-batch consistency, ensuring reproducibility results and a secure supply throughout the assay lifecycle.

Bio-Rad''s stock of recombinant, monoclonal, and anti-idiotypic antibodies continues to expand. These critical antibody reagents assist researchers in implementing bioanalytical assays for checkpoint inhibitor drugs, according to Amanda Turner, a bio-Rad product manager and Life Science Group. The introduction of TrailBlazer Antibodies to the range offers greater flexibility for bioanalytical assay design.

Anti-cemiplimab antibodies are approved for in vitro research purposes and for commercial use, which are providing in vitro testing services to assist preclinical and clinical medicine and biosimilar development.

You may also like: